TRCT
ONSIZ

Tower Research Capital (TRC)’s Oncobiologics, Inc. Series B Warrant ONSIZ Stock Holding History

Tower Research Capital (TRC)’s Portfolio ONSIZ Stock Details ONSIZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-240
Closed – – 5035
2016
Q2 		$0 Buy
+240
New +$126 ﹤0.01% 5360

Other funds holding ONSIZ

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Tower Research Capital (TRC)'s ONSIZ Position: Q3 2016 in Review

Tower Research Capital (TRC) sold out of Oncobiologics, Inc. Series B Warrant (ONSIZ) in Q3 2016, closing a stake of 240 shares.

Tower Research Capital (TRC) first reported a position in ONSIZ in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 11 funds tracked by Wall St. Rank hold ONSIZ as of Q3 2016.

  • Tower Research Capital (TRC) reported no remaining Oncobiologics, Inc. Series B Warrant position as of Q3 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 240 Oncobiologics, Inc. Series B Warrant shares in Q3 2016.
  • Tower Research Capital (TRC) first reported a position in Oncobiologics, Inc. Series B Warrant in Q2 2016 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Oncobiologics, Inc. Series B Warrant position peaked at $0 in Q2 2016.
  • 11 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series B Warrant as of Q3 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2016, filed 8 Nov 2016.